{"classes":[{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because no one had lost response.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"16 weeks"},{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because no one had lost response.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"32 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.88","upperLimit":"0.99","value":"0.97"}]}],"title":"48 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.82","upperLimit":"0.97","value":"0.92"}]}],"title":"64 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.80","upperLimit":"0.96","value":"0.91"}]}],"title":"80 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.80","upperLimit":"0.96","value":"0.91"}]}],"title":"96 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.76","upperLimit":"0.93","value":"0.87"}]}],"title":"112 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.72","upperLimit":"0.91","value":"0.84"}]}],"title":"128 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.72","upperLimit":"0.91","value":"0.84"}]}],"title":"144 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.70","upperLimit":"0.90","value":"0.82"}]}],"title":"160 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.66","upperLimit":"0.87","value":"0.79"}]}],"title":"176 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.64","upperLimit":"0.86","value":"0.77"}]}],"title":"192 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.60","upperLimit":"0.83","value":"0.73"}]}],"title":"208 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.60","upperLimit":"0.83","value":"0.73"}]}],"title":"224 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.60","upperLimit":"0.83","value":"0.73"}]}],"title":"240 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.60","upperLimit":"0.83","value":"0.73"}]}],"title":"256 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"Duration of the absence of phlebotomy eligibility is defined as the time from the first occurrence of absence of phlebotomy eligibility until the date of the first documented progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy","id":"OG000","title":"Ruxolitinib"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprises all participants to whom study treatment had been assigned by randomization. Duration of the absence of phlebotomy eligibility was pre-specified in the protocol to be analyzed for the ruxolitinib arm only considering the study design which allowed crossover for the BAT arm beginning at Week 32.","reportingStatus":"POSTED","timeFrame":"256 Weeks","title":"Duration of the Absence of Phlebotomy Eligibility","type":"SECONDARY","unitOfMeasure":"probability"}